- Projects & figures
- News & Events
- Managing your project
- About ERC
CRISPR is a widely used molecular biology tool exploiting an immune process discovered in bacteria. Dr David Bikard studies CRISPR in bacterial cells, in conjunction with different DNA repair systems, to create even newer tools. He hopes to gain insight into bacterial genetics, and develop increasingly effective medical treatments.
Severe traffic jams not only have an impact on mobility, they also raise environmental and health issues linked to fuel consumption and air and noise pollution. Prof. Ludovic Leclercq is developing new traffic control models that could tackle road congestion while integrating a green dimension.
For the first time ever, a team of scientists and clinicians led by the EU-funded researcher Mickael Tanter has managed to record the brain activity of a premature new-born baby during resting and during an epileptic seizure. Using a non-invasive ultrasound technology, this world premiere is a real game changer for researchers and the medical profession, offering a massive range of applications in neuroimaging and beyond. It is published today in Science Translational Medicine.
Pour la toute première fois, une équipe de scientifiques et des cliniciens dirigée par le chercheur Mickael Tanter, financé par l'UE, a réussi à enregistrer l'activité cérébrale d'un nouveau-né prématuré en phase de repos et lors d'une crise d'épilepsie. À l'aide d'une technologie d'échographie non invasive, cette première mondiale marque un véritable tournant dans le domaine de la recherche et la pratique médicale. Elle offre par ailleurs une vaste gamme d'applications en neuroimagerie et au-delà. L'étude est publiée aujourd'hui dans Science Translational Medicine.
Headscarves, mosques and halal shops — many EU citizens are Muslims, but visible signs of their faith are often viewed with distrust. What some Europeans see as a right to express their identity, others regard as a threat to societal core values. Insights from ERC-funded research into emblematic controversies may help to find a way forward.
Through her work with the fruit fly Drosophila santomea, Dr Virginie Orgogozo aims to answer one of the most challenging questions of modern evolutionary biology: how do observable characteristics change between species and yet remain stable in a given species?
While women inherit two X chromosomes, the expressions of one of them is shut down during embryonic development. Men have one X chromosome and one Y chromosome. The switching off of women’s second X chromosome is thought to compensate for the presence of only one X in males versus two in females, to balance for X-linked gene products between the sexes. X-chromosome inactivation is also one of the clearest examples of what epigenetic mechanisms do to our genetic material: the DNA of the genes on the X is still present but not actively expressed or needed. Prof. Edith Heard was awarded ERC grants to understand the intricate processes behind the phenomenon, with unexpected results that changed the way gene regulation is now looked at.
Most of our actions can have an impact on the environment, be it minor, long-lasting or simply irreversible. But how can this effect be measured, avoided, predicted? What are the specificities of long-term risks and how can collective decisions be taken effectively to tackle those threats?
As Europe continues to confront the consequences of the 2008 financial crisis it becomes ever-more important to fathom not only how Europe can return to productive levels of employment, but why it is failing to do so. Professor Pissarides’s ERC research examines both what kind of jobs Europeans do and future trends in employment. He will present his research to the public at TEDx Brussels event on 1 December.
In 2012, 2.8 million people in the EU were diagnosed with cancer. It is the second most common cause of death in the Union – three out of 10 deaths for men, and two out of 10 deaths for women – a figure that is expected to rise due to the ageing European population. Dr Danijela Matic Vignjevic’s STARLIN project is using ERC funding to understand how normal cells become cancerous and spread.